Quarterly report · Q2
4886.TEDINET S100S71T
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥31.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥60.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥30.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥3.1bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥2.9bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥3.1bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥5.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.0bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥5.4bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.0bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥4.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥2.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥91.9bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥87.1bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥86.2bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥33.3bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥32.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥58.6bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥54.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥52.0bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥17.4bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥14.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥19.4bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.5bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.2bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.1bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥3.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥1.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥199m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥2.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥145.93 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥95.41 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥150.08 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥83.18 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36.25 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 63.8% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.3% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥108m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥80m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥27m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | −¥61m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥27m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥27m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥585m |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥44m |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥28.4bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥28.4bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥3.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥31.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥31.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥27m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥3.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥114m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥86m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥28m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | −¥20m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥28m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥28m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥473m |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥231m |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥26.9bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥26.9bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥3.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥30.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥30.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥28m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥3.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 457
| Item | Context | Value | Unit |
|---|---|---|---|
| Extraordinary income | Prior1YTDDuration | 32000000 | JPY |
| Extraordinary income | CurrentYTDDuration | 2314000000 | JPY |
| Income before income taxes | Prior1YTDDuration | 3019000000 | JPY |
| Income before income taxes | CurrentYTDDuration | 5410000000 | JPY |
| Income taxes current | Prior1YTDDuration | 693000000 | JPY |
| Income taxes current | CurrentYTDDuration | 1424000000 | JPY |
| Income taxes deferred | Prior1YTDDuration | -19000000 | JPY |
| Income taxes deferred | CurrentYTDDuration | -143000000 | JPY |
| Income taxes | Prior1YTDDuration | 673000000 | JPY |
| Income taxes | CurrentYTDDuration | 1280000000 | JPY |
| Profit loss | Prior1YTDDuration | 2346000000 | JPY |
| Profit loss | CurrentYTDDuration | 4129000000 | JPY |
| Profit loss attributable to owners of parent | Prior1YTDDuration | 2346000000 | JPY |
| Profit loss attributable to owners of parent | CurrentYTDDuration | 4129000000 | JPY |
| Profit loss | Prior1YTDDuration | 2346000000 | JPY |
| Profit loss | CurrentYTDDuration | 4129000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1YTDDuration | 519000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | CurrentYTDDuration | -134000000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | Prior1YTDDuration | 13000000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | CurrentYTDDuration | -15000000 | JPY |
| Share of other comprehensive income of associates accounted for using equity method oci | Prior1YTDDuration | 371000000 | JPY |
| Share of other comprehensive income of associates accounted for using equity method oci | CurrentYTDDuration | 271000000 | JPY |
| Other comprehensive income | Prior1YTDDuration | 905000000 | JPY |
| Other comprehensive income | CurrentYTDDuration | 121000000 | JPY |
| Comprehensive income | Prior1YTDDuration | 3251000000 | JPY |
| Comprehensive income | CurrentYTDDuration | 4251000000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 3251000000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 4251000000 | JPY |
| Income before income taxes | Prior1YTDDuration | 3019000000 | JPY |
| Income before income taxes | CurrentYTDDuration | 5410000000 | JPY |
| Depreciation and amortization ope cf | Prior1YTDDuration | 1527000000 | JPY |
| Depreciation and amortization ope cf | CurrentYTDDuration | 1376000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | Prior1YTDDuration | 132000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | CurrentYTDDuration | 130000000 | JPY |
| Interest and dividends income ope cf | Prior1YTDDuration | -185000000 | JPY |
| Interest and dividends income ope cf | CurrentYTDDuration | -189000000 | JPY |
| Interest expenses ope cf | Prior1YTDDuration | 25000000 | JPY |
| Interest expenses ope cf | CurrentYTDDuration | 21000000 | JPY |
| Loss gain on sales of investment securities ope cf | Prior1YTDDuration | -32000000 | JPY |
| Loss gain on sales of investment securities ope cf | CurrentYTDDuration | -2314000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YTDDuration | -1876000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYTDDuration | -2137000000 | JPY |
| Decrease increase in inventories ope cf | Prior1YTDDuration | -1096000000 | JPY |
| Decrease increase in inventories ope cf | CurrentYTDDuration | -899000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YTDDuration | -27000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYTDDuration | 1586000000 | JPY |
| Other net ope cf | Prior1YTDDuration | 419000000 | JPY |
| Other net ope cf | CurrentYTDDuration | 719000000 | JPY |
| Subtotal ope cf | Prior1YTDDuration | 1907000000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | 3703000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |